Business Context and Reporting Period
This Form 8-K filing by Genprex, Inc. (GNPX) is dated October 13, 2025. The report addresses critical corporate governance and regulatory compliance matters, specifically the company's status regarding Nasdaq listing requirements and the implementation of a reverse stock split. The filing also provides updates on the company's clinical trial programs in oncology and diabetes gene therapy.
Key Financial Metrics and Listing Status
The filing does not provide a full set of financial statements (revenue, profit, or cash flow) as this is a current report on specific events. However, it discloses specific equity metrics relevant to listing compliance:
- Stockholders' Equity: As of June 30, 2025, stockholders' equity was reported at $1,391,195, which is below the Nasdaq minimum requirement of $2.5 million.
- Bid Price: The company failed to maintain the minimum $1.00 per share bid price required for continued listing.
- Listing Status: The Nasdaq Hearings Panel granted an exception allowing continued listing through October 31, 2025, with discretionary potential for extension to February 9, 2026.
Material Changes and Corporate Actions
The most significant material change disclosed is the approval and filing of a Certificate of Amendment to effect a one-for-fifty (1:50) reverse stock split. Key details include:
- Effective Date: The split will take effect at 12:01 a.m. Eastern Time on October 21, 2025.
- Trading Impact: The stock will begin trading on a split-adjusted basis on October 21, 2025. The trading symbol will remain "GNPX," but the CUSIP number will change to 372446-302.
- Shareholder Impact: Every 50 shares will be converted into 1 share. Fractional shares will be rounded up to the next whole share. Options and warrants will be adjusted accordingly.
- Reasoning: This action is intended to help the company regain compliance with the Nasdaq Minimum Bid Price Requirement.
Outlook, Management Commentary, and Risks
Clinical Program Updates:
- Acclaim-1 (NSCLC): Currently enrolling in the Phase 2a expansion. Interim analysis expected in the second half of 2026. The trial has FDA Fast Track Designation.
- Acclaim-3 (ES-SCLC): Currently enrolling in the Phase 2 expansion. Interim analysis expected in the second half of 2026. The trial has FDA Fast Track and Orphan Drug Designations.
- Diabetes Gene Therapy (GPX-002): Preclinical studies are ongoing. The company plans to submit a request to the FDA for a meeting regarding IND-enabling studies by the end of 2025.
Risks and Contingencies:
- Delisting Risk: There is no assurance the Nasdaq Panel will grant an extension beyond October 31, 2025, or that the reverse stock split will successfully restore compliance. Failure to comply could result in delisting, reduced liquidity, and difficulty raising capital.
- Capital Needs: The company may need to raise additional capital to meet the Minimum Stockholders' Equity Requirement, which could result in dilution.
- Market Volatility: The reverse stock split could negatively affect the stock price or liquidity, and there is no guarantee the post-split price will be maintained.
Investor Verification Checklist
- Verify the execution of the 1:50 reverse stock split on October 21, 2025, and the new CUSIP number (372446-302).
- Monitor the stock's closing bid price to determine if it sustains the $1.00 threshold for 10 consecutive business days post-split.
- Confirm whether the company secures a Nasdaq extension beyond October 31, 2025, or achieves full compliance by that date.
- Review upcoming filings for any capital raise announcements intended to address the stockholders' equity deficit.
- Track enrollment progress and interim analysis timelines for the Acclaim-1 and Acclaim-3 clinical trials as stated for 2026.